Alzinova

Name

Alzinova

Legal name

Alzinova AB

Website

https://alzinova.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Alzheimer's Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Alzheimer's immunotherapy
• Amyloid-beta oligomers
• Therapeutic vaccines
• Monoclonal antibodies
• Biopharmaceutical drug discovery

Headquarters

HQ city

Gothenburg

HQ country

Sweden

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pre-commercial / Product Revenue (Future): Alzinova is a clinical-stage biopharma company with no current commercial products or revenue. The company is developing ALZ-101 (vaccine in Phase 1b) and ALZ-201 (monoclonal antibody in preclinical development) for Alzheimer's disease treatment. Future revenue will come from product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Alzinova fundamentally develops disease-modifying immunotherapies targeting toxic amyloid-β oligomers in Alzheimer's disease. Its lead candidate, ALZ-101, is an oligomer-specific therapeutic vaccine that stimulates patients' immune systems to produce antibodies against toxic oligomers, currently in Phase 1b clinical trials. Its second candidate, ALZ-201, is an oligomer-specific monoclonal antibody in preclinical development, intended for stand-alone or combination therapy. Both candidates are built on the proprietary AβCC Peptide™ Technology platform that enables specific oligomer targeting with unprecedented discrimination from monomers and fibrils.

Product overview

Alzinova is a Swedish clinical-stage biopharma company pioneering the development of disease-modifying treatments against Alzheimer's disease. The company operates a portfolio-based approach with two main programs: ALZ-101 (therapeutic vaccine in Phase 1b clinical trials) and ALZ-201 (monoclonal antibody in preclinical development). Both products are generated from the proprietary AβCC Peptide™ Technology platform, which enables specific targeting of toxic amyloid-beta oligomers. The company is headquartered in Mölndal, Sweden, with shares listed on Nasdaq First North Growth Market.

Differentiator

Problem solved

Functional benefit

Products and services

• ALZ-101 ALZ-101 is an oligomer-specific therapeutic vaccine designed to stimulate the patient's immune system to produce antibodies against toxic amyloid-β oligomers for the treatment of Alzheimer's disease. The vaccine completed Phase 1b clinical trials demonstrating a 95%+ immune responder rate over an 84-week study, good tolerability, acceptable safety profile, and antibodies reaching the central nervous system. It is being prepared for Phase 2 clinical studies.
• ALZ-201 ALZ-201 is an oligomer-specific humanized monoclonal antibody (originally murine IgG isotype) with extremely high oligomer specificity that does not react with functional (non-aggregated) or inert (fibrillar) amyloid-β and does not cross-react with Aβ40. It is intended for use as a stand-alone disease-modifying therapy or as a complement to the ALZ-101 vaccine, and is currently in preclinical development with humanization completed.

Quantifiable outcome

• 95%+ immune response rate (31 of 32 patients generated desired immune response)
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• FujirebiocoreStrategic or Co-development Partner · 24 June 2026Letter of Intent signed regarding potential commercialization of blood-based Alzheimer's diagnostic test. This partnership could enable broader patient access to diagnostic capabilities supporting ALZ-101 treatment. Alzinova CEO Tord Labuda discussed the partnership in the context of precision vaccines and diagnostics integration.
• Ernst & Young ABcoreOthersThe company's auditor is Ernst & Young AB, Gothenburg. Linda Sallander is the auditor in charge and partner at EY with many years of experience in leading audit engagements for listed companies and Life Science sector. Member of FAR, the association of Swedish professional accountants.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• BioArctic AB: Swedish clinical-stage biotech developing immunotherapies and antibodies for Alzheimer's disease, including the lecanemab antibody (marketed as LEQEMBI by Eisai/Biogen). Most directly comparable peer given shared Swedish origin, AD focus, and antibody/immunotherapy approach.
• AC Immune SA: Swiss clinical-stage biotech developing both active immunotherapy vaccines (ACI-35) and passive antibodies against Tau and Aβ for Alzheimer's disease. Highly comparable in therapeutic modality mix (vaccine + mAb) and target indication.
• Prothena Corporation: Ireland/US biotech developing monoclonal antibodies targeting misfolded proteins including amyloid-beta (PRX012) for Alzheimer's. Direct competitor in the anti-Aβ passive immunotherapy space with similar scientific approach.
• Cognition Therapeutics: US clinical-stage biotech focused on small-molecule therapeutics for Alzheimer's disease and other neurodegenerative disorders. Comparable as a small-cap AD-focused company navigating similar clinical development and partnership pathways.

Broad incumbents

• Eisai Co., Ltd. Japanese Big Pharma with the leading FDA-approved anti-amyloid antibody LEQEMBI (lecanemab). Major incumbent in the AD space and a potential partner/acquirer for Alzinova given active Big Pharma discussions.
• Biogen Inc. US Big Pharma with the leading AD franchise (aducanumab withdrawn, LEQEMBI co-commercialized with Eisai). Co-promoter of LEQEMBI and major incumbent competitor; potential partner for Alzinova's oligomer-specific approach.

Emerging players

• Cassava Sciences: US clinical-stage biotech developing simufilam for Alzheimer's disease. Similar profile as a small-cap, single-indication-focused AD biotech navigating late-stage clinical development and partnership dynamics.
• Anavex Life Sciences: US clinical-stage biotech developing ANAVEX compounds (e.g., blarcamesine) for Alzheimer's and Rett syndrome. Comparable as a small-cap neurodegenerative-disease biotech with limited near-term revenue.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInse.linkedin.com/company/alzinova-ab

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alzinova